Korean Pro-Innovation Pricing Steps Draw Mixed Responses
Amid pharma industry’s repeated calls to improve the drug pricing system and properly reflect R&D cost of novel drugs, South Korea released steps that include hiking prices of “global innovative novel drugs” and biomedicines. Response is mixed, with foreign pharmas complaining the steps focus mainly on domestically developed drugs.
You may also be interested in...
The US and South Korea's agreement to modify Korea's drug pricing system for innovative drugs raises concerns over an increased price burden for global drugs in the country.
Amid an escalating tussle with the health ministry over the level of South Korean drug prices, foreign pharma firms operating in the country are now proposing the launch of a new joint study on the issue with the incoming government.
South Korea unveils its first comprehensive plan for the overall development of the health care industry, with a focus on developing novel therapies for rare and incurable diseases, precision and regenerative medicine, and customized health management systems, with the aims of improving care, controlling costs, and raising global industry competitiveness.